BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 9744771)

  • 1. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin.
    Schulte TW; Neckers LM
    Cancer Chemother Pharmacol; 1998; 42(4):273-9. PubMed ID: 9744771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depletion of p185erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity.
    An WG; Schnur RC; Neckers L; Blagosklonny MV
    Cancer Chemother Pharmacol; 1997; 40(1):60-4. PubMed ID: 9137531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
    Bonvini P; Gastaldi T; Falini B; Rosolen A
    Cancer Res; 2002 Mar; 62(5):1559-66. PubMed ID: 11888936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disruption of the EF-2 kinase/Hsp90 protein complex: a possible mechanism to inhibit glioblastoma by geldanamycin.
    Yang J; Yang JM; Iannone M; Shih WJ; Lin Y; Hait WN
    Cancer Res; 2001 May; 61(10):4010-6. PubMed ID: 11358819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts.
    Nimmanapalli R; O'Bryan E; Bhalla K
    Cancer Res; 2001 Mar; 61(5):1799-804. PubMed ID: 11280726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
    Beliakoff J; Bagatell R; Paine-Murrieta G; Taylor CW; Lykkesfeldt AE; Whitesell L
    Clin Cancer Res; 2003 Oct; 9(13):4961-71. PubMed ID: 14581371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin.
    Schulte TW; Akinaga S; Soga S; Sullivan W; Stensgard B; Toft D; Neckers LM
    Cell Stress Chaperones; 1998 Jun; 3(2):100-8. PubMed ID: 9672245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The heat shock protein 90-binding geldanamycin inhibits cancer cell proliferation, down-regulates oncoproteins, and inhibits epidermal growth factor-induced invasion in thyroid cancer cell lines.
    Park JW; Yeh MW; Wong MG; Lobo M; Hyun WC; Duh QY; Clark OH
    J Clin Endocrinol Metab; 2003 Jul; 88(7):3346-53. PubMed ID: 12843186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Geldanamycin, an inhibitor of the chaperone activity of HSP90, induces MAPK-independent cell cycle arrest.
    Bedin M; Gaben AM; Saucier C; Mester J
    Int J Cancer; 2004 May; 109(5):643-52. PubMed ID: 14999769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway.
    Schulte TW; Blagosklonny MV; Romanova L; Mushinski JF; Monia BP; Johnston JF; Nguyen P; Trepel J; Neckers LM
    Mol Cell Biol; 1996 Oct; 16(10):5839-45. PubMed ID: 8816498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity.
    Bisht KS; Bradbury CM; Mattson D; Kaushal A; Sowers A; Markovina S; Ortiz KL; Sieck LK; Isaacs JS; Brechbiel MW; Mitchell JB; Neckers LM; Gius D
    Cancer Res; 2003 Dec; 63(24):8984-95. PubMed ID: 14695217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest.
    Srethapakdi M; Liu F; Tavorath R; Rosen N
    Cancer Res; 2000 Jul; 60(14):3940-6. PubMed ID: 10919672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of telomerase activity by geldanamycin and 17-allylamino, 17-demethoxygeldanamycin in human melanoma cells.
    Villa R; Folini M; Porta CD; Valentini A; Pennati M; Daidone MG; Zaffaroni N
    Carcinogenesis; 2003 May; 24(5):851-9. PubMed ID: 12771028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Geldanamycin prevents nuclear translocation of mutant p53.
    Dasgupta G; Momand J
    Exp Cell Res; 1997 Nov; 237(1):29-37. PubMed ID: 9417863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone.
    Clarke PA; Hostein I; Banerji U; Stefano FD; Maloney A; Walton M; Judson I; Workman P
    Oncogene; 2000 Aug; 19(36):4125-33. PubMed ID: 10962573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin.
    da Rocha Dias S; Friedlos F; Light Y; Springer C; Workman P; Marais R
    Cancer Res; 2005 Dec; 65(23):10686-91. PubMed ID: 16322212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
    Smith V; Sausville EA; Camalier RF; Fiebig HH; Burger AM
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):126-37. PubMed ID: 15841378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Ah receptor is a sensitive target of geldanamycin-induced protein turnover.
    Chen HS; Singh SS; Perdew GH
    Arch Biochem Biophys; 1997 Dec; 348(1):190-8. PubMed ID: 9390191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules.
    Soga S; Neckers LM; Schulte TW; Shiotsu Y; Akasaka K; Narumi H; Agatsuma T; Ikuina Y; Murakata C; Tamaoki T; Akinaga S
    Cancer Res; 1999 Jun; 59(12):2931-8. PubMed ID: 10383157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90.
    Kelland LR; Sharp SY; Rogers PM; Myers TG; Workman P
    J Natl Cancer Inst; 1999 Nov; 91(22):1940-9. PubMed ID: 10564678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.